KELOWNA, British Columbia, Sept. 26, 2022 (GLOBE NEWSWIRE) -- Tryp Therapeutics, Inc. (CSE: TRYP) (OTCQB: TRYPF) ("Tryp" or the "Company"), a clinical-stage biotechnology company focused on developing psilocybin-based compounds for diseases with unmet medical needs, today announced the filing of two new provisional patent applications. One patent application, #63/405,786, is for the use of psilocybin for the treatment of patients with fibromyalgia and the other application, #63/375,305, expands the IP related to the Company’s development of TRP-8803.

See more here:
Tryp Therapeutics Strengthens Intellectual Property Portfolio with Provisional Patent Applications for Fibromyalgia Treatment and for Crystalline...

Upgrades will enhance and automate the patient candidate experience for all NeuroStar providers, leading to faster patient identification of those in need of treatment Upgrades will enhance and automate the patient candidate experience for all NeuroStar providers, leading to faster patient identification of those in need of treatment

Go here to read the rest:
Neuronetics Launches Innovations To NeuroStar® Advanced Therapy’s Proprietary TrakStar® Platform

ISELIN, N.J., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a pre-commercial biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced it will present at Eyecelerator @ AAO 2022 taking place Thursday, September 29, 2022 in Chicago, Illinois.

See the original post:
Outlook Therapeutics® to Present at Eyecelerator @ AAO 2022

SAN DIEGO, Sept. 26, 2022 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") announced today that the company has completed enrollment of its latest Phase 2 clinical study of RTX for treating moderate-to-severe osteoarthritis of the knee pain (OAK).

Go here to see the original:
Sorrento Therapeutics Completes Enrollment of Phase 2 Clinical Trial of Resiniferatoxin (RTX) for Treatment of Knee Pain in Moderate to Severe...

CANTON, Mass., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced that third quarter of fiscal year 2022 financial results will be reported after the market closes on Wednesday, November 9th.

Go here to read the rest:
Organogenesis Holdings Inc. to Report Third Quarter of Fiscal Year 2022 Financial Results on November 9, 2022

NEW YORK, Sept. 26, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (“Y-mAbs”, NASDAQ: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that Adium Pharma S.A. (“Adium”) has submitted a regulatory filing for DANYELZA® (naxitamab-gqgk) for the treatment of patients with relapsed/refractory high-risk neuroblastoma to the Brazilian Health Regulatory Agency, Agência Nacional de Vigilância Sanitária (“Anvisa”).

View post:
Y-mAbs Announces Regulatory Filing for DANYELZA® (naxitamab-gqgk) in Brazil

CUMBERLAND, Md., Sept. 26, 2022 (GLOBE NEWSWIRE) -- RS BioTherapeutics, whose mission is to harness its strong and thorough understanding of the endocannabinoid system (ECS) to research, develop and commercialize interventions to address chronic and acute pulmonary (lung) inflammation-based diseases, is pleased to announce that is has secured a $3 million Seed II round of funding.

See original here:
RS BioTherapeutics Secures $3 Million Seed II Round of Funding

Parallel processing using TCXpress™ and iTCXpress™ platforms significantly increases throughput, reduces the cost and shortens the timing of identifying novel TCRs Parallel processing using TCXpress™ and iTCXpress™ platforms significantly increases throughput, reduces the cost and shortens the timing of identifying novel TCRs

Go here to read the rest:
BlueSphere Bio Presents Data Demonstrating Efficiency of Parallel TCR Capture and Bioinformatics Platforms at 7th Annual CAR-TCR Summit

- Order for Approximately $10 Million Funded by the European Commission –

See original here:
SIGA Announces Approximately $16 Million of International Procurement Orders Received in August and Early September for Oral TPOXX® (Tecovirimat)

Company announcementOrphazyme A/SNo. 36/2022             www.orphazyme.comCompany Registration No. 32266355

The rest is here:
Orphazyme reports financial results in Interim Report First Half 2022

Guerbet obtains one million euros of public funding from Bpifrance (France 2030 investment plan) for a project developing artificial intelligence for the early detection of pancreatic cancer

Here is the original post:
Guerbet obtains one million euros of public funding from Bpifrance (France 2030 investment plan) for a project developing artificial intelligence for...

Mupadolimab clinical trial in China will be conducted by Angel Pharmaceuticals Mupadolimab clinical trial in China will be conducted by Angel Pharmaceuticals

Originally posted here:
Corvus Pharmaceuticals Announces Partner Angel Pharmaceuticals Received IND Approval for Phase 1/1b Clinical Trial of Mupadolimab (Anti-CD73) in China

- $238 Million in Upfront Payment Received at Closing with Additional $136.5 Million in Potential Milestone Payments Plus Royalties -

More here:
Chimerix Announces Closing of TEMBEXA Sale to Emergent BioSolutions

AUSTIN, Texas, Sept. 26, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing a novel oral therapeutic candidate, LUM-201, through Phase 2 clinical trials for Pediatric Growth Hormone Deficiency (PGHD), announced that Lumos Pharma management will participate in a panel discussion and host one-on-one meetings at the Cantor Neurology & Psychiatry Conference in October.

See original here:
Lumos Pharma to Participate in the Cantor Neurology & Psychiatry Conference

EDISON, N.J., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH”), hepatocellular carcinoma (“HCC”), and other chronic liver diseases, today announced that its Chief Medical Officer, Todd Hobbs, MD, will participate in the “Novel Targets in Oncology: Risk vs. Reward” panel at the Cantor Oncology, Hematology & HemeOnc Conference on Wednesday, September 28, 2022 at 9:00 a.m. Eastern Time at the New York Palace Hotel.

See more here:
Hepion Pharmaceuticals to Participate in the Cantor Oncology, Hematology & HemeOnc Conference

CAMBRIDGE, Mass., Sept. 26, 2022 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from solid tumors, today announced that management will participate in a fireside chat at the Jefferies Cell & Genetic Medicine Summit on Thursday, September 29 at 2:00PM E.T.

Read the original post:
TCR² Therapeutics to Present at the Jefferies Cell & Genetic Medicine Summit

PHILADELPHIA, Sept. 26, 2022 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (ANPC), a biotechnology company with operations in the United States and China focused on early cancer screening and detection, announced that on September 26, 2022, the Company and a group of nine institutional and individual investors (the “Investors”) have signed legally binding agreements for the investment in the Company by the Investors of approximately $3.67 Million.

View original post here:
AnPac Bio and New Investor Group Sign Equity Investment Totaling $3.67 Million

CAMBRIDGE, Mass., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare and genetically defined diseases, today announced the grant of inducement equity awards outside of the Company’s 2013 Stock Incentive Plan to its newly appointed Chief Financial Officer, Cecilia Jones. The grants were approved by the Board of Directors effective as of September 26, 2022 as inducements material to Ms. Jones entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).

Read the original:
Agios Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Financial Officer

OSLO, Norway, Sept. 27, 2022 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, today announced positive clinical results from the Phase 1/2 open label, dose escalation trial of Nykode’s T cell focused pan-SARS-CoV-2 vaccine candidate (VB10.2210) in healthy individuals who were previously vaccinated with an approved mRNA vaccine. T cell responses were analyzed by ex vivo ELISpot up until day 35. VB10.2210 induced broad and strong T cell responses, dominated by killer CD8 T cells, against both Spike- and non-Spike antigens. It was safe and well-tolerated at all three dose levels.

More:
Nykode Therapeutics Announces Positive Results from the Phase 1/2 Open Label, Dose Escalation Trial of its T Cell Focused SARS-CoV-2 Vaccine Candidate

Ad hoc announcement pursuant to Art. 53 LR

Follow this link:
Idorsia secures additional cash by entering into a building sale and leaseback agreement